Home › Merck KGaA, Darmstadt, Germany, And Pfizer Announce FDA Orphan Drug Designation For Investigational Immunotherapy Avelumab In Merkel Cell Carcinoma
 

Keywords :   


Merck KGaA, Darmstadt, Germany, And Pfizer Announce FDA Orphan Drug Designation For Investigational Immunotherapy Avelumab In Merkel Cell Carcinoma

2015-09-30 08:25:02| drugdiscoveryonline News Articles

Merck KGaA, Darmstadt, Germany, and Pfizer recently announced that the US Food and Drug Administration (FDA) has granted orphan drug designation for the investigational cancer immunotherapy avelumab* for the treatment of Merkel cell carcinoma (MCC), a rare and aggressive type of skin cancer

Tags: germany cell drug announce

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
08.06Eastern North Pacific Tropical Weather Outlook
08.06Atlantic Tropical Weather Outlook
08.06Eastern North Pacific Tropical Weather Outlook
08.06Atlantic Tropical Weather Outlook
07.06The rise and rise of fashion giant Shein
07.06Tories pledge to 'back drivers' with new law
07.06Labour vows to 'pull up shutters' for small business
07.06USGBC Applauds Final Definition of a Zero Emissions Building
More »